Objective: The objective of the study was to evaluate the safety and efficacy of ocrelizumab (OCR) and rituximab (RTX) in multiple sclerosis. Methods: This was a retrospective single-centre study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results